Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
RegulatoryapprovedTAUKLARIFYPositive
AI Analysis
Summary
Lantheus announced FDA approval of TAUKLARIFY (Florquinitau F 18 Injection), an F18-labeled tau PET imaging agent for Alzheimer's disease. This represents a significant regulatory milestone for the company's diagnostic imaging portfolio.
Outcome Details
FDA approval of TAUKLARIFY for tau PET imaging in Alzheimer's Disease
Importance:8/10
Sentiment:
0.95
FDA approvaldiagnostic imagingPET imagingAlzheimer's diseaseneurology
Related Companies
Read the original article
Published by yahoo_finance on August 14, 2026 12:00 PM